Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Arterioscler+Thromb+Vasc+Biol 2016 ; 36 (11): 2143-51 Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Thrombotic Stroke: Neuroprotective Therapy by Recombinant Activated Protein C #MMPMID27758767
Griffin JH; Mosnier LO; Fernández JA; Zlokovic BV
Arterioscler Thromb Vasc Biol 2016[Nov]; 36 (11): 2143-51 PMID27758767show ga
Activated protein C (APC), derived from the plasma protease zymogen, protein C, is antithrombotic and anti-inflammatory. In preclinical injury models, recombinant APC provides neuroprotection for multiple injuries, including ischemic stroke. APC acts directly on brain endothelial cells and neurons by initiating cell signaling that requires multiple receptors. Two or more major APC receptors mediate APC?s neuroprotective cell signaling. When bound to endothelial cell protein C receptor, APC can cleave protease activated receptor 1 causing biased cytoprotective signaling that reduces ischemia-induced injury. Pharmacologic APC alleviates bleeding induced by tissue plasminogen activator (tPA) in murine ischemic stroke studies. Remarkably, APC?s signaling promotes neurogenesis. The signaling-selective recombinant variant of APC, ?3K3A-APC?, was engineered to lack most of APC?s anticoagulant activity but retain APC?s cell signaling actions. Recombinant 3K3A-APC is in ongoing NIH-funded clinical trials for ischemic stroke.